How to Inject Lantus: Step-by-Step Technique
Inject Lantus subcutaneously once daily in the abdomen, thigh, or arm with a 4-5mm needle at 90 degrees. Rotate sites and hold 10 seconds after injecting.
Insulin Glargine
16 source-based articles maintained by the HealthRX.com Editorial Team.
16articles
6topic areas covered
May 25, 2026latest review
Insulin Glargine library
Showing 16 of 16 clinical reviews.
How to Safely Stop Lantus (Insulin Glargine): A Clinician-Guided Discontinuation Protocol
Evidence-based guidance on safely tapering or stopping insulin glargine (Lantus), including who qualifies, stepdown protocols, monitoring benchmarks, and when discontinuation is medically inappropriate.
Insulin Glargine (Lantus) Complete Drug-Drug Interaction Profile
A clinician-grade review of every major drug-drug interaction with insulin glargine (Lantus, Basaglar, Semglee, Toujeo), including hypoglycemia potentiators, hyperglycemic antagonists, and masking agents.
Insulin Glargine (Lantus) Safety Signals and FDA Actions
A breakdown of every major FDA safety signal, label revision, and post-marketing action tied to insulin glargine (Lantus), including the ORIGIN trial cancer debate and hypoglycemia warnings.
Lantus Adult (30 to 49) Dosing: Insulin Glargine Initiation, Titration, and Optimization
Evidence-based insulin glargine (Lantus) dosing guide for adults aged 30 to 49 with type 1 or type 2 diabetes, including initiation protocols, titration algorithms, and real-world clinical considerations.
Lantus Cost vs Alternatives: Insulin Glargine Price and Clinical Comparison Guide
Compare Lantus (insulin glargine) cost against biosimilars, other basal insulins, and GLP-1 combinations. Includes mechanism, dosing, trial data, and a clinical decision framework for switching.
Lantus Dosing in Renal Impairment: A Clinical Guide to Insulin Glargine and Kidney Disease
Evidence-based guidance on insulin glargine (Lantus) dosing in renal impairment, including CKD-stage-specific recommendations, hypoglycemia risk, and ORIGIN trial data. prepared by the HealthRX.com Editorial Team.
Lantus Geriatric (65+) Dosing: Insulin Glargine Dose Adjustments for Older Adults
Evidence-based guide to insulin glargine (Lantus) dosing in adults 65 and older, covering starting doses, titration, hypoglycemia risk, renal adjustments, and deprescribing strategies.
Lantus Hair and Skin Changes: What Patients and Clinicians Need to Know
A thorough clinical review of insulin glargine (Lantus) effects on hair and skin, covering injection-site reactions, lipohypertrophy, lipoatrophy, and dermatologic considerations, with primary-literature citations and practical management guidance.
Lantus History and Development: How Insulin Glargine Changed Basal Insulin Therapy
Insulin glargine's A21 glycine and B31-B32 arginine modifications shift the isoelectric point to pH 6.7, causing microprecipitation at physiologic pH 7.4.
Lantus Manufacturing and Supply: What the Product Records Show
Read the evidence on Lantus manufacturing, pens and vials, dated shortages, biosimilar products, storage differences and finding an obtainable refill.
Lantus Mechanism of Action: Full Pathway Explained
Insulin glargine swaps A21 asparagine for glycine and adds arginine at B31 and B32, shifting its isoelectric point from ~5.4 to ~6.7 for depot release.
Lantus Missed-Dose Protocol: What to Do When You Skip Insulin Glargine
Evidence-based protocol for handling missed doses of insulin glargine (Lantus), including timing thresholds, hypoglycemia risk, and when to contact your prescriber.
Lantus Pharmacokinetics: How Insulin Glargine Is Absorbed, Distributed, Metabolized, and Eliminated
MD-level review of insulin glargine (Lantus) pharmacokinetics covering absorption mechanics, microprecipitate formation, active metabolites M1 and M2, distribution volume, and elimination half-life with PubMed-cited evidence.
Lantus Storage, Stability & Shelf Life: Complete Insulin Glargine Guide
Does Lantus need refrigerating? Yes: unopened vials and pens keep at 36 to 46 °F until expiry date. Once opened, store at room temp and toss in 28 days.
Switching To and From Lantus (Insulin Glargine): A Complete Clinical Protocol Guide
Evidence-based protocols for switching between Lantus (insulin glargine U-100) and other basal insulins, including Toujeo, Tresiba, Basaglar, Semglee, and NPH. Covers dose conversion ratios, titration schedules, and monitoring requirements with PubMed and FDA citations.